

# Christian Borel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6085268/publications.pdf>

Version: 2024-02-01

31  
papers

1,131  
citations

567281

15  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1924  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of immune response biomarkers (PD-1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas. <i>Oncology Reports</i> , 2021, 45, 1273-1283.	2.6	8
2	Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes. <i>Current Opinion in Oncology</i> , 2021, 33, 160-167.	2.4	9
3	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC). <i>Journal of Clinical Oncology</i> , 2011, 29, 463-475.	10.7	95
4	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Clinical Oncology</i> , 2021, 39, 6020-6020.	1.6	4
5	Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3038.	3.7	7
6	Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 714551.	2.8	2
7	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , 2020, 69, 531-539.	12.1	97
8	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2691.	3.7	39
9	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, e000664.		48
10	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	6.4	4
11	Abstract P3-09-06: Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor- $\beta$ 2 and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase I cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, e000664.		5
12	Hidden intra-mandibular carcinoma cuniculatum appearing in a patient with metastatic prostate cancer: a case report. <i>BMC Oral Health</i> , 2019, 19, 54.	2.3	4
13	Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 83.	7.1	63
14	NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 6083-6083.	1.6	43
15	Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?. <i>Anti-Cancer Drugs</i> , 2018, 29, 287-294.	1.4	3
16	Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3084-3090.	1.6	55
17	Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3077-3083.	1.6	107
18	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	1.6	70

#	ARTICLE	IF	CITATIONS
19	Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer. <i>Oncotarget</i> , 2018, 9, 37581-37588.	1.8	3
20	Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas. <i>Chinese Clinical Oncology</i> , 2018, 7, 60-60.	1.2	6
21	Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey. <i>Oncology</i> , 2017, 93, 11-17.	1.9	7
22	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	2.8	40
23	Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3601-3601.	1.6	12
24	Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3531-3531.	1.6	5
25	PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6086-6086.	1.6	18
26	Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes. <i>Oral Oncology</i> , 2013, 49, 482-491.	1.5	41
27	Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. <i>Oral Oncology</i> , 2013, 49, 9-14.	1.5	71
28	Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. <i>Acta Oto-Laryngologica</i> , 2008, 128, 706-712.	0.9	37
29	Docetaxel Plus Gemcitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head And Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 278-282.	1.3	15
30	Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 2866-2872.	1.6	160
31	Prognostic indicators for survival in head and neck squamous cell carcinomas: Analysis of a series of 621 cases. <i>Head and Neck</i> , 2005, 27, 801-808.	2.0	53